In-Vitro Diagnostics Market Analysis to 2017

News provided by

Feb 19, 2013, 06:05 ET

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In-Vitro Diagnostics Market Analysis to 2017

http://www.reportlinker.com/p01103486/In-Vitro-Diagnostics-Market-Analysis-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The global in-vitro diagnostics (IVD) market is going through a very exciting phase, offering immense opportunities for players involved in the business. The market, which on one hand, is struggling to maintain a foothold in the unstable economy of Europe is growing astoundingly at a high double-digit growth rate in emerging economies of India, China, and Brazil.

In their latest research study, "In-Vitro Diagnostics Market Analysis to 2017", RNCOS analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 52.4 Billion in 2012, is expected to grow at a CAGR of 7% during 2012-2017.

In the report, the IVD market has been studied on three distinct levels: Regional, Clinical and Player level. For regional analysis, key IVD markets that together constitute around 95% of the global market, have been profiled. Further, the market has been divided into eight distinct clinical segments and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various clinical segments and highlighted the clinical segments that offer the maximum opportunity for growth in each region.

Besides, our team has also analyzed the revenue generated from each clinical segment to recognize key segments that offer very high growth rates. The study further delves into the business dynamics of major players in the industry that together form more than 70% of the global IVD market. To provide a thorough understanding of the Company's business model, Company's current and historical financials have been analyzed. Also, the Company's revenue from IVD has been depicted with a further breakup by clinical segment. The study also portrays each Company's strengths and weaknesses that will help the reader to better position its company vis-à-vis competition.

1. Analyst View

2. Research Methodology

3. In Vitro Diagnostic Market Overview

3.1 Introduction
3.2 What is In Vitro Diagnostics?
3.3 Market Size and Growth

4. Clinical Segmentation Outlook 2017

(For all clinical segments, the section contains following testing market information)
Market by Region (%), 2012
Market by Players (%), 2012
Testing Market (Billion US$), 2012-2017
4.1 Point-of-Care Diagnostics
4.2 Immunochemistry
4.3 Clinical Chemistry
4.4 Molecular Diagnostics
4.5 Hematology
4.6 Microbiology
4.7 Hemostasis
4.8 Immunohematology

5. Geographical Segmentation Outlook 2017

(For all countries, the section contains following information)
Market by Clinical Segment (%), 2012
In Vitro Diagnostic Market (Billion US$), 2012-2017
Market by Clinical Segment (%), 2017
Key Market Drivers
5.1 America
5.1.1 United States
5.1.2 Canada
5.1.3 Brazil
5.1.4 Mexico
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 Italy
5.2.4 United Kingdom
5.2.5 Spain
5.3 Asia-Pacific
5.3.1 Japan
5.3.2 China
5.3.3 India

6. Industry Trends

6.1 Fast Emerging Niche: Devices to Capture Circulating Tumor Cells
6.2 On the Horizon: Non-Invasive Genetic Tests for Cancer
6.3 Non-Invasive Prenatal Diagnostics Market Witnesses Boom
6.4 Companion Diagnostics Partnerships Gear Up
6.5 Predictive Cancer Diagnostic Test Market Rockets Northwards
6.6 POCT: Expanding Avenues into Multiple Disease Diagnosis

7. Competitive Landscape

(For all players, the section contains following information)
Business Overview
Key Financials
Strengths and Weaknesses
Recent Developments
7.1 Market Share of Top Players
7.2 Key Players
7.2.1 Abbott Laboratories
7.2.2 Alere, Inc.
7.2.3 Becton Dickinson
7.2.4 Bayer HealthCare
7.2.5 Beckman Coulter
7.2.6 Biomerieux
7.2.7 Johnson and Johnson
7.2.8 Life Technologies Corporation
7.2.9 Medtronic, Inc.
7.2.10 Qiagen NV
7.2.11 Roche Holding Ltd
7.2.12 Sysmex Corporation
7.2.13 Siemens HealthCare
7.2.14 Thermo Fisher Scientific

List of Figures:

Figure 3-1: Global - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 4-1: Global - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 4-2: Global - Point-of-Care Testing Market by Region (%), 2012
Figure 4-3: Global - Point-of-Care Testing Market by Players (%), 2012
Figure 4-4: Global - Point-of-Care Testing Market (Billion US$), 2012-2017
Figure 4-5: Global - Immunochemistry Testing Market by Region (%), 2012
Figure 4-6: Global - Immunochemistry Testing Market by Players (%), 2012
Figure 4-7: Global - Immunochemistry Testing Market (Billion US$), 2012-2017
Figure 4-8: Global - Clinical Chemistry Testing Market by Region (%), 2012
Figure 4-9: Global - Clinical Chemistry Testing Market by Players (%), 2012
Figure 4-10: Global - Clinical Chemistry Testing Market (Billion US$), 2012-2017
Figure 4-11: Global - Molecular Diagnostics Market by Region (%), 2012
Figure 4-12: Global - Molecular Diagnostics Market by Players (%), 2012
Figure 4-13: Global - Molecular Diagnostics Market (Billion US$), 2012-2017
Figure 4-14: Global - Hematology Testing Market by Region (%), 2012
Figure 4-15: Global - Hematology Testing Market by Players (%), 2012
Figure 4-16: Global - Hematology Testing Market (Billion US$), 2012-2017
Figure 4-17: Global - Microbiology Testing Market by Region (%), 2012
Figure 4-18: Global - Microbiology Testing Market by Players (%), 2012
Figure 4-19: Global - Microbiology Testing Market (Billion US$), 2012-2017
Figure 4-20: Global - Hemostasis Testing Market by Region (%), 2012
Figure 4-21: Global - Hemostasis Testing Market by Players (%), 2012
Figure 4-22: Global - Hemostasis Testing Market (Billion US$), 2012-2017
Figure 4-23: Global - Immunohematology Testing Market by Region (%), 2012
Figure 4-24: Global - Immunohematology Testing Market (Billion US$), 2012-2017
Figure 5-1: Global - In Vitro Diagnostic Market by Region (%), 2012
Figure 5-2: Global - In Vitro Diagnostic Market by Region (%), 2017
Figure 5-3: US - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-4: US - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-5: US - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-6: Canada - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-7: Canada - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-8: Canada - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-9: Brazil - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-10: Brazil - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-11: Brazil - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-12: Mexico - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-13: Mexico - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-14: Mexico - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-15: Europe - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-16: Europe - In Vitro Diagnostic Market by Country (%), 2012
Figure 5-17: Europe - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-18: Europe - In Vitro Diagnostic Market by Country (%), 2017
Figure 5-19: Europe - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-20: Germany - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-21: Germany - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-22: Germany - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-23: France - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-24: France - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-25: France - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-26: Italy - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-27: Italy - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-28: Italy - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-29: UK - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-30: UK - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-31: UK - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-32: Spain - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-33: Spain - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-34: Spain - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-35: Japan - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-36: Japan - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-37: Japan - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-38: China - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-39: China - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-40: China - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-41: India - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-42: India - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-43: India - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 7-1: Global - In Vitro Diagnostic Market by Players (%), 2012
Figure 7-2: Abbott Laboratories - Break up of Revenue by Business Segment (%), 2012
Figure 7-3: Abbott Laboratories - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-4: Alere Inc. - Break up of Revenue by Business Segment (%), 2011
Figure 7-5: Alere Inc. - Diagnostic Division Revenue by Segment (%), 2011
Figure 7-6: Becton Dickinson - Break up of Revenue by Business Segment (%), 2012
Figure 7-7: Becton Dickinson - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-8: Bayer HealthCare - Break up of Revenue by Business Segment (%), 2011
Figure 7-9: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2011
Figure 7-10: Beckman Coulter - Break up of Revenue by Business Segment (%), 2010
Figure 7-11: Beckman Coulter - Diagnostic Division Revenue by Segment (%), 2010
Figure 7-12: Biomerieux - Break up of Revenue by Business Segment (%), 2012
Figure 7-13: Biomerieux - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-14: Johnson & Johnson - Break up of Revenue by Business Segment (%), 2011
Figure 7-15: Life Technologies Corporation - Break up of Revenue by Business Segment (%), 2011
Figure 7-16: Medtronic Inc. - Break up of Revenue by Business Segment (%), 2012
Figure 7-17: Qiagen NV - Break up of Revenue by Business Segment (%), 2011
Figure 7-18: Roche Holdings Ltd - Break up of Revenue by Business Segment (%), 2011
Figure 7-19: Roche Holdings Ltd - Diagnostic Division Revenue by Segment (%), 2011
Figure 7-20: Sysmex Corp. - Break up of Revenue by Business Segment (%), 2012
Figure 7-21: Sysmex Corp. - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-22: Siemens HealthCare - Diagnostic Division Revenue by Segment (%), FY 2012
Figure 7-23: Thermo Fisher Scientific - Break up of Revenue by Business Segment (%), 2011

List of Tables:

Table 4-1: Global - In Vitro Diagnostic Market by Clinical Segment (Billion US$), 2012
Table 4-2: Global - In Vitro Diagnostic Market by Clinical Segment (Billion US$), 2017
Table 5-1: Europe - Percentage of People Aged 65+ Years in Top-5 IVD Markets (2012 & 2017)
Table 7-1: Abbott Laboratories - Key Financials (Million US$), 2010-2012
Table 7-2: Abbott Laboratories - Strengths and Weaknesses
Table 7-3: Alere Inc. - Key Financials (Million US$), 2009-2011
Table 7-4: Alere Inc. - Strengths and Weaknesses
Table 7-5: Becton Dickinson - Key Financials (Million US$), 2010- 2012
Table 7-6: Becton Dickinson - Strengths and Weaknesses
Table 7-7: Bayer HealthCare - Key Financials (Million US$), 2009-2011
Table 7-8: Bayer HealthCare- Strengths and Weaknesses
Table 7-9: Beckman Coulter - Strengths and Weaknesses
Table 7-10: Biomerieux - Key Financials (Million (€), 2010 & 2011
Table 7-11: Biomerieux - Strengths and Weaknesses
Table 7-12: Johnson & Johnson - Key Financials (Million US$), 2010-2012
Table 7-13: Johnson & Johnson - Strengths and Weaknesses
Table 7-14: Life Technologies Corporation - Key Financials (Million US$), 2010-2012
Table 7-15; Life Technologies Corporation - Strengths and Weaknesses
Table 7-16: Medtronic Inc. - Key Financials (Million US$), 2010-2012
Table 7-17; Medtronic Inc. - Strengths and Weaknesses
Table 7-18: Qiagen NV - Key Financials (Million US$), 2009-2011
Table 7-19: Qiagen NV - Strengths and Weaknesses
Table 7-20: Roche Holding Ltd - Key Financials (Million US$), 2010-H1 2012
Table 7-21; Roche Holding Ltd - Strengths and Weaknesses
Table 7-22: Sysmex Corp. - Key Financials (Million US$), 2010- 2012
Table 7-23; Siemens AG - Key Financials (Million €), FY 2010 to FY 2012
Table 7-24: Siemens - Strength and Weaknesses
Table 7-25: Thermo Fisher Scientific - Key Financials (Million US$) 2010-2012 (Q1-Q3)
Table 7-26: Thermo Fisher Scientific Inc. - Strengths and Weaknesses